


PHARMACEUTICAL 2023



Cryoport Inc. Rank 186 of 446







PHARMACEUTICAL 2023



Cryoport Inc. Rank 186 of 446

The relative strengths and weaknesses of Cryoport Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cryoport Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Cryoport Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 75% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	604,176
Cost of Goods Sold	133,404
Intangible Assets	342,126
Liabilities, Current	40,851
Liabilities, Non-Current	25,172
Other Assets	28,841
Other Compr. Net Income	-33,306
Other Expenses	2,239
Other Liabilities	416,885
Other Net Income	-3,190
Other Revenues	237,277
Property and Equipment	63,603
Research and Development	15,722
Selling, General and Administrative Expense	120,055

Output Variable	Value in 1000 USD
Assets	1,038,746
Liabilities	482,908
Expenses	271,420
Revenues	237,277
Stockholders Equity	555,838
Net Income	-37,333
Comprehensive Net Income	-53,986
Economic Capital Ratio	119%

